Escitalopram for agitation in Alzheimer’s disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial

Conflicts of interest: D.P.D. reports consulting for Eisai, Acadia, and Avanir. L.S.S. reports grants from NIA and the State of California, within 3 years and during the conduct of the study; grants from Eli Lilly, Merck, Novartis, Roche, Biogen, and UCSD and personal fees from AC Immune, Allergan, Avraham, Axovant, Boehringer Ingelheim, Cognition, Lilly Merck, Neurim, Roche, Takeda, Toyama, and vTv outside the submitted work. T.K.R. has received research support from Brain Canada, Brain and Behavior Research Foundation, BrightFocus Foundation, Canada Foundation for Innovation, Canada Research Chair, Canadian Institutes of Health Research, Centre for Aging and Brain Health Innovation, National Institutes of Health, Ontario Ministry of Health and Long-Term Care, Ontario Ministry of Research and Innovation, and the Weston Brain Institute. Z.I. has received funding from Brain Canada,…